Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C26H32N2O4 |
| Molecular Weight | 436.5433 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(CC1CC2=CC=CC=C2C1)NC[C@@H](O)COC3=C(C=CC(CCC(O)=O)=C3)C#N
InChI
InChIKey=NJBFJCJKWWIKRD-HSZRJFAPSA-N
InChI=1S/C26H32N2O4/c1-26(2,14-19-11-20-5-3-4-6-21(20)12-19)28-16-23(29)17-32-24-13-18(8-10-25(30)31)7-9-22(24)15-27/h3-7,9,13,19,23,28-29H,8,10-12,14,16-17H2,1-2H3,(H,30,31)/t23-/m1/s1
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SB-423562
Created by
admin on Sat Dec 16 00:36:48 GMT 2023 , Edited by admin on Sat Dec 16 00:36:48 GMT 2023
|
PRIMARY | NPS Pharmaceuticals (NASDAQ: NPSP) has initiated a Phase 2a study to evaluate the safety and tolerability of NPSP795 in adult patients with Autosomal Dominant Hypocalcemia (ADH), an ultra-rare genetic disorder of calcium homeostasis. ADH is caused by mutations of the calcium-sensing receptor (CaSR) gene that increase the sensitivity of the receptor to serum calcium. NPSP795 is a selective calcium receptor antagonist, which binds to the CaSR and decreases its sensitivity to serum calcium. Its mechanism of action is believed to restore the normal physiological action of the CaSR and address the underlying molecular defect in ADH to return to normal calcium homeostasis. The company expects to report preliminary top-line data from the study in late 2014 or early 2015. | ||
|
615K7YBS59
Created by
admin on Sat Dec 16 00:36:48 GMT 2023 , Edited by admin on Sat Dec 16 00:36:48 GMT 2023
|
PRIMARY | |||
|
351490-27-2
Created by
admin on Sat Dec 16 00:36:48 GMT 2023 , Edited by admin on Sat Dec 16 00:36:48 GMT 2023
|
PRIMARY | |||
|
9910902
Created by
admin on Sat Dec 16 00:36:48 GMT 2023 , Edited by admin on Sat Dec 16 00:36:48 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PRODRUG (METABOLITE ACTIVE)
SALT/SOLVATE (PARENT)
